With the skyrocketing costs related to the treatment of cancer, it is logical that significant emphasis should be placed on research and development efforts to prevent this devastating disease. Indeed, strategic prevention initiatives have the potential for the greatest impact on the societal and economic burden of cancer. Fortunately, there has been a rapid increase in our understanding of the interactions at the molecular level between genetic factors and the environment that lead to the development and progression of cancer, and these insights are providing important opportunities for targeted interventions to prevent cancer. But how do we identify and prioritize these potential initiatives, and more importantly, how can we successfully implement them?

The national C-Change Summit has led to a plan for developing specific, feasible actions to:

- substantially increase investment by the federal government and the pharmaceutical, biotech, and food industries in discovery and development of cancer preventatives, both protective drugs and vaccines
- change policies, procedures, and laws to encourage investment by industry
- modify the regulatory burden on the Food and Drug Administration for balanced consideration of the benefits as well as risks of preventive agents
- modify policies of the Centers for Medicare and Medicaid Services and private payers for coverage for effective cancer preventive agents
- educate the public and health care providers on important benefits of cancer prevention

At UPMC Cancer Centers and the University of Pittsburgh Cancer Institute (UPCIC), we are setting a national example in the implementation of strategies that begin to address many of these goals. We are educating state and federal officials about the need for more resources, through tours of our community cancer centers as well as the Hillman Cancer Center. We are implementing research programs to track lifestyle patterns and study the impact of those patterns on the prevention of cancer. And we are developing the prevention tools, in the form of cancer vaccines and natural chemicals in foods, coupled with very promising laboratory tests of blood for early detection of cancer, that one day will lead to a future without cancer.
Travelers driving into the City of Waterford follow a beautiful coastal road – Port Lairge on one side and a towering green hillside on the other. In the distance is a billowing white banner. “WE NEED RADIOTHERAPY NOW.”

It’s a striking message against this otherwise serene vista.

Waterford, located in the Southeast region of Ireland, is more than 100 miles from the nearest radiation oncology centers in Dublin and Cork. Patients undergoing radiation therapy travel up to six hours round-trip daily to receive treatment. To address this burden, patients and health advocates are desperately seeking new alternatives for treatment more convenient to Waterford.

ENTER UPMC CANCER CENTERS.
Following the successful hub-and-satellite model established in western Pennsylvania, UPMC Cancer Centers is making its first foray into international care with the opening of UPMC Whitfield Cancer Centre. The University of Pittsburgh Medical Center (UPMC) has proven expertise in management and delivery of care to patients worldwide. This new radiation oncology facility now brings state-of-the-art cancer treatment to patients in Waterford.

“The dire need for radiotherapy in Waterford has been well-documented,” explains Charles E. Bogosta, executive vice president for Strategic Business Initiatives and Cancer Services, UPMC. “It presented a perfect opportunity to export the cancer technology, expertise, and treatment delivery that we’ve successfully developed, refined, and implemented here in western Pennsylvania to an international site.”

UPMC Whitfield Cancer Centre is a joint program with Euro Care International, an Irish health care infrastructure development company. The cancer center is housed in Whitfield Clinic, a 65-bed hospital facility offering elective surgery, diagnostic testing, and physiotherapy, owned and operated by Euro Care International.

UPMC Whitfield Cancer Centre will offer state-of-the-art radiation oncology and imaging services, including intensity-modulated radiation therapy (IMRT) and its newest form, image-guided radiation therapy (IGRT), as well as PET/CT imaging.

continued on page 4


IMRT uses three-dimensional images obtained through PET/CT to more precisely target radiation beams directly to a tumor, sparing the surrounding healthy, noncancerous tissue, and resulting in fewer treatment-related side effects for the patient. The precise nature of the treatment requires a highly trained medical physicist and sophisticated equipment — making the treatment too prohibitive for many cancer centers. However, through the telemedicine network already established here in western Pennsylvania, UPMC is able to extend this expertise to Waterford.

"Through UPMC Cancer Centers’ telemedicine network, the expertise and treatment planning needed for IMRT are available centrally at the Pittsburgh hub," explains Jeffrey Shogan, MD, director for Clinical Business and Practice Operations, UPMC Cancer Centers. "Information is easily shared by the two sites through the use of a telecommunications system, ensuring that the patient in Waterford receives the same state-of-the-art care available in the United States."

IGRT, the next phase of IMRT, also will be available at the Waterford location. IGRT helps the radiation oncologist to deliver radiation therapy more precisely to a tumor by tracking movement. As the tumor moves due to normal breathing patterns, adjustments are made to allow for that movement, making the delivery of the radiation even more exact.

UPMC Whitfield Cancer Centre will begin treating patients in mid-November 2006. UPMC Cancer Centers is also exploring expanded ventures in Ireland, including a new radiation therapy center in Dublin, as well as in the United Kingdom and Italy.

In the more than 100 years since radiation was first used as a treatment for cancer, scientists have worked to better understand its biological effects. With advancements in technology resulting in more sophisticated equipment, oncologists are now able to aim the radiation beam more precisely to target tumors, resulting in better outcomes for cancer patients.

By using the OBI to generate high-quality, real-time x-ray images of the targeted area immediately before each treatment, the team is able to ensure that only the cancerous area is being radiated. Zeroing in on the tumor while adapting for breathing motion reduces the risk of complications and minimizes side effects for the patient.

“The treatment plan must be carefully designed to protect the healthy tissue and organs around the tumor — in the case of lung cancer, the heart and the esophagus. We also are concerned about compromising the patient’s ability to breathe,” Dr. Heron explains.

To have all of these capabilities fully integrated with the treatment machine has given us the power to truly tailor cancer treatment for each and every patient, which should result in not only better quality of life, but better outcomes,“ says Dr. Heron.

The Trilogy system is currently housed in the Mary Hillman Jennings Radiation Oncology Center located at UPMC Shadyside — the hub for radiation oncology services at UPMC Cancer Centers. A second machine with OBI is located at UPMC Passavant, offering easier access to this advanced technology to patients in the northern suburbs of Pittsburgh.

"Information is easily shared by the two sites through the use of a telecommunications system, ensuring that the patient in Waterford receives the same state-of-the-art care." — Jeffrey Shogan, MD

At UPMC Cancer Centers, a multi-disciplinary team of radiation oncologists, medical physicists, pathologists, surgeons, and other cancer care specialists is using advanced diagnostics, innovative treatment modalities, and cutting-edge technology to continually refine comprehensive treatment strategies that are tailored to each individual patient’s situation.

“With advanced medical physics and treatment planning, combined with equipment that allows us to track the movement of tumors at the time of treatment, we are seeing dramatic effects for our patients,” explains Dwight Heron, MD, director of radiation oncology services at UPMC Cancer Centers.

Minimizing Patient Risk

UPMC Cancer Centers is one of the first in western Pennsylvania to employ the Trilogy system, an advanced linear accelerator — the machine used to deliver radiation to a tumor. With Trilogy, radiation oncologists are able to treat tumors in difficult to reach areas with minimal risks compared to conventional surgical or radiation approaches.

The Trilogy system features an On-Board Imager (OBI), a CT-like scanner that is used to take images of the cancerous areas to better track tumor movement. This allows the radiation oncologist to make adjustments during the treatment to ensure that the radiation is focused on the cancerous areas.

“Before we had technologies like the Trilogy machine, radiation delivery was like uniform streams of water pouring from a showerhead,” Dr. Heron explains. “Now we are able to lessen, or altogether stop, some streams of radiation that could affect healthy tissue located around the tumor. This allows us to make individual adjustments based on what we’re seeing that day.”

Timing Treatment

Dr. Heron and his clinical team are now using this sophisticated technology to treat lung cancer — one of the most difficult cancers to treat with radiation. Since lung tumors often move with breathing, accurate targeting of the radiation beam is difficult to achieve without treating large volumes of normal tissues.

“The treatment plan must be carefully designed to protect the healthy tissue and organs around the tumor — in the case of lung cancer, the heart and the esophagus. We also are concerned about compromising the patient’s ability to breathe,” Dr. Heron explains.
What is skin cancer?

The many types of skin cancer are divided into two categories: non-melanoma and melanoma. Basal cell and squamous cell are common types of non-melanoma, which are less aggressive and have higher survival rates. Of these common cancers, malignant melanoma is the most life-threatening and occurs when cancer cells arise from the melanocyte cells of the skin. Melanocytes make melanin, which gives skin its natural pigment and is found in the epidermis, or outer layer of the skin. As skin is exposed to the sun, these cells produce more pigment, resulting in a tan.

Over the past two decades, the incidence of melanoma has doubled in the United States. “About 55,000 people develop melanoma each year, and it’s the leading cause of death in women ages 25 to 35,” says John Kirkwood, MD, professor of medicine and dermatology; vice chairman for clinical research, Department of Medicine, UPMC, and director of the internationally renowned University of Pittsburgh Cancer Institute Melanoma and Skin Cancer Program. “The Melanoma and Skin Cancer Program was founded by Dr. Kirkwood more than 20 years ago,” says Ronald Herberman, MD, director, UPMC Cancer Centers and University of Pittsburgh Cancer Institute, adding, “It was one of the first to be started at UPCI.”

Cutting-edge detection and treatment

UPCI and UPMC Cancer Centers offer a variety of new and innovative detection and treatment options for patients worldwide. “Most skin cancers can be treated effectively if detected early,” explains Louis D. Falo Jr., MD, PhD, professor and chairman of the Department of Dermatology, UPMC. To enable early detection, UPMC physicians offer comprehensive skin examinations including dermoscopic evaluation and systematic whole body imaging services. For those diagnosed with melanoma, treatments include surgery to remove tumors or extract melanoma and surrounding tissue; sentinel node mapping, which provides a “tracking system” for melanoma that has spread to the region of the lymph nodes; and wide local excision with or without the removal of additional lymph nodes (lymphadenectomy). Skin grafting and newer plastic surgery procedures provide easier recovery for the patient with less scarring. If the risk of relapse is predicted to be elevated, some patients may undergo immunologic treatments.

A true advocate of clinical trials

UPMC is already known for its world-class melanoma center, thanks to cutting-edge research. Dr. Kirkwood is an advocate of clinical trials and is actively involved in several, including the largest peptide vaccine clinical trial in the country. “We pioneered the first FDA-approved melanoma therapy for the prevention of relapse, which has been a major step forward in treating skin cancer,” says Dr. Kirkwood, highlighting a study published in the July 2006 issue of the Journal of Clinical Oncology. The study finds that when a high dose of the protein interferon (HD IL-2) is administered prior to treatment, it is highly effective for the treatment of patients with high-risk, stage III melanomas, improving overall survival rates and in some cases, rendering patients disease-free. Twenty patients with palpable, regional lymph node metastatic melanoma were enrolled in the clinical trial between January 2001 and February 2005. At a median follow up of 18 months, half of the participants showed no evidence of recurrent disease. “This is the first reported evaluation of HD IL-2 given as a single-agent immunotherapeutic therapy for treatment of melanoma,” says Dr. Kirkwood, “and we are very excited about the results as well as the future for this type of treatment.”

Nearly one million Americans will be diagnosed with skin cancer this year.

It is 2006, and the expression “killer tan” has taken on a new meaning. The days of using baby oil to achieve the ultimate tan have passed, and the urban myth that a visit to the tanning bed will lessen the chances of getting cancer due to reduced exposure time has been debunked. Scientists at the University of Pittsburgh Cancer Institute (UPCI) and UPMC Cancer Centers are collaborating on several promising new research projects in an effort to bump skin cancer out of its spot as the number one cancer in the country.

by Carey Anne Zucca
When melanoma spreads beyond the possibility of surgical treatment, professionals at UPMC Cancer Centers and UPCI turn to immunotherapy. Most recently, Drs. Kirkwood and Falo tested a type of immunotherapy in which dendritic cells are activated to combat cancer by exposing them to fragments of viruses and bacteria to mimic danger. Because they exist in the skin, dendritic cells are usually the first to recognize the presence of a foreign body, or antigen. Although dendritic cells—often dubbed the "policemen" of the immune system—play a vital role in the initiation of immune responses, cancer cells often elude them.

**ABOUT 55,000 PEOPLE DEVELOP MELANOMA EACH YEAR, AND IT’S THE LEADING CAUSE OF DEATH IN WOMEN AGES 25 TO 35**

In this novel approach, dendritic cells are both "activated" and programmed to stimulate immune responses against cancer antigens. In preclinical studies published in the journal Cancer Research, the dendritic cell approach to melanoma therapy has been successful. "Now that we have identified how to take the brakes off the immune system and trigger it to fight cancer cells, we can shrink melanoma tumors and help prevent relapse," says Dr. Kirkwood.

"Interestingly," says Dr. Falo, "this approach was first discovered in humans, rather than animals, as is usually the case. We have now validated the approach in animal models and are using results from animal studies to improve vaccines for patients." Drs. Kirkwood and Falo agree their findings show promise for the development of vaccines that require cellular immunity, including those directed toward viral and bacterial infections and cancer. In the next year, they expect to initiate a clinical trial based on this approach for patients with melanoma.

Get to Know Your Skin

The best option for combating cancer is early detection. In addition to performing regular breast or testicular self-examinations, it is important to get to know your skin. High-risk melanoma patients, including people with a family history of the disease, may employ the help of a "mole map" by visiting Larisa J. Geskin, MD, FAAD, assistant professor of dermatology, and director of the Cutaneous Oncology and Photopheresis Center.

Mole mapping or body mapping involves taking digital photographs of the entire body. Specially trained medical photographers use digital cameras in a room equipped with special color-managed lighting to create a mosaic of the patient’s skin. Each photo concentrates on a particular body part, where high-resolution digital images of every mole in that area are taken. The mosaic includes areas that are not normally viewed, like the soles of the feet and the top of the shoulders. In the end, more than 40 photos make up the patient’s body mosaic. Dr. Geskin and her team of physicians use the photos at each examination to do side-by-side comparisons of the patient and his or her digital history.

In April 2006, retired United States Steel Corporation CEO and chairman, Thomas Usher, and his wife Sandra donated $1 million to the University of Pittsburgh Cancer Institute’s melanoma program. The Sandra and Thomas Usher Endowed Chair in Melanoma will aid in the diagnosis and treatment of melanoma. Mr. Usher is a melanoma survivor and patient of Dr. Kirkwood’s who was diagnosed with the disease in 1998.

Funding from The Sandra and Thomas Usher Endowed Chair in Melanoma will dramatically augment the growth and productivity of the melanoma program under Dr. Kirkwood's direction. The chair will provide permanent funding for the recruitment of new faculty who ultimately will be Dr. Kirkwood’s successors in leading melanoma research at UPCI.

The best option for combating skin cancer is early detection.

**EARLY DETECTION FOR COMBATING SKIN CANCER IS**

Get to Know Your Skin

The best option for combating cancer is early detection. In addition to performing regular breast or testicular self-examinations, it is important...
It was only six months after treatment for head and neck cancer when Lynn Durkin found out that she was pregnant. She was happy, if not stunned, by the news that came after surgery to remove 28 lymph nodes, multiple doses of chemotherapy, and more than 30 radiation treatments for a cancer most often diagnosed in older men who drink and smoke. After treatment and follow-up scans, she was deemed cancer free by her medical team and gave birth to a healthy baby girl in February 2006. Ms. Durkin now finds herself thinking about why she ended up with this particular cancer, her risk for recurrence, and perhaps most importantly, her young daughter Jillian’s risk for disease in the future.

How can we find a cure for cancer if we don’t know what may have caused it in the first place?
When you have cancer, you ask yourself, ‘What is it that made me get this cancer? Was it something in my family? Was it something in the air?’

You worry about all of that,” says Ms. Durkin. “And, when you become pregnant, you want to know what you may be genetically passing on to your child. I would love to know that my daughter will never have to think about cancer.

Emanuela Taioli, MD, PhD, an expert in cancer risk and individual susceptibility and director of Cancer Prevention and Population Science at the University of Pittsburgh Cancer Institute, hopes to gain the insight needed to answer these questions by examining the factors that put a person at risk for cancer. She is conducting research to better understand how lifestyle, genetics, and the environment are linked to disease by examining the ways these factors interact.

In May, Dr. Taioli’s research was given a major boost from The Arnold D. Palmer 2003 Charitable Trust in the form of a $2 million gift to create The Arnold Palmer Endowed Chair in Cancer Prevention. The funding has enabled her to begin a partner project with Panera restaurants in Pittsburgh to develop a registry of individuals who will be surveyed about their health histories and behavioral choices. Through the surveys and follow-up interviews, Dr. Taioli, a professor of epidemiology at the University of Pittsburgh Graduate School of Public Health and of hematology and oncology at the University of Pittsburgh School of Medicine, will examine the differences between people who are healthy and those who develop disease. By studying the lifestyles and genetics of people who remain cancer-free, Dr. Taioli and her co-investigator, Lyn Robertson, DrPH, hope to develop a model of cancer prevention that will shed light on the factors that cause cancer and how they interact with biology to put people at risk.

In another project, Dr. Taioli will follow cancer patients over time to learn more about their risks not only for recurrence, but for the development of new, so-called second primary cancers. Dr. Taioli explains that while cancer prevention is traditionally aimed at people who have never had cancer, it is also important for survivors, who should continue to be screened and fully monitored to learn more about their unique risks for the development of new cancers.

‘As more and more people are living with cancer — the National Cancer Institute estimates that more than 10 million people living in the United States either have had cancer or are currently under treatment for it — we need to shift our focus to address the needs of survivors who are at great risk for recurrence and new cancers,’ says Dr. Taioli. ‘The most significant impact that can be made on cancer survival is to prevent the disease from occurring in the first place through an increased understanding of cancer risk and individual susceptibility. Greater knowledge will lead us to effective methods for preventing cancer, bringing renewed hope to cancer survivors and their children who may have concerns about their own risks for cancer.’

Lynn Durkin cannot agree more. “How can we find a cure for cancer if we don’t know what may have caused it in the first place? That is the key.”
Patients who come to UPMC Cancer Centers are given the best treatment and care available by a comprehensive team of oncologists, nurses, social workers, and other health care professionals. There is another very important component of that team: volunteers. More than 200 volunteers at UPMC Cancer Centers and the University of Pittsburgh Cancer Institute (UPCI) help to improve the quality of life for patients and their families by providing support on many levels throughout the cancer continuum.

**Volunteers Improving Quality of Life for Patients and their Families**

by Carey Anne Zucca

Serving within five designated areas based on their skills and interests, including patient and family support, laboratory research, administrative support, the Healing Power of the Arts, and special events, volunteers range in age from teenagers to senior citizens. Each gives his or her time for a variety of reasons. Some volunteers are students who are interested in gaining experience in research laboratories or other areas, some have lost a loved one to cancer and want to give back as part of the healing process, and others are retired members of the community who have time to give.

“Our volunteers are a very dedicated group,” says Lisa Huntley, director, UPMC Cancer Centers and UPCI Volunteer and Community Services. “Volunteers come to the Hillman Cancer Center for a variety of reasons but they all offer compassion and their commitment of time to help our patients and staff.”

After completing a thorough application process, each volunteer is placed in an area that will best serve him or her, as well as the patients. “We do our best to meet the volunteer’s expectations while fulfilling patient needs,” explains Zuleikha Bjork, assistant program coordinator, UPMC Cancer Centers and UPCI Volunteer and Community Services. “It’s really a partnership among the staff, volunteers, and patients.”

Unique Programs for Patients

Volunteers at UPMC Cancer Centers coordinate a variety of programs and engaging activities for patients and family members. For example, through the Healing Power of the Arts Program, volunteers host craft classes on the oncology inpatient units located at UPMC Shadyside at least twice a week for cancer patients, family, and staff. The volunteers do not need to be trained artists; for example, class instructors have included a stay-at-home mom, a working professional, and a cancer survivor — all people who simply enjoy sharing their crafts. The arts program also features local musicians, such as those from the Carnegie Mellon Arts Alliance, who perform for the patients on the oncology inpatient units or at the Hillman Cancer Center Atrium.

Volunteering is not limited to site visits at Hillman Cancer Center and the oncology inpatient units at UPMC. A group of volunteers known as “Project of Love” work out of their Beaver County homes to make turbans and pillows for cancer patients. These are sent to Hillman Cancer Center as well as the other cancer center locations for distribution. Another group of volunteers who are part of the US TOO! Prostate Peer Counselors Group donate their time by making phone calls to newly diagnosed patients to offer support.

Local grade school students from the Pittsburgh area contribute their time and talents by making cards for patients on holidays, birthdays, and other special occasions.
tored closely by his cancer care team. He is now 16 years old, and patiently waiting to begin driving.

“The care my mother and my neighbor received at Hillman Cancer Center inspired me to volunteer there,” says Ms. Kirsch.

Ms. Kirsch volunteers for at least four hours one night a week during the school year. She has developed many wonderful relationships with patients since she began volunteering in October 2004 and has become known as “the lady with the crazy tights.” “If I make one person laugh or smile just by looking at my tights, I know I’ve brought him or her out of his or her element even for a moment,” she says.

Supporting an Ongoing Need

In addition to daily support, Volunteers and Community Services also hosts a number of special community events throughout the year to honor patients with cancer, while raising money and awareness. The Daffodil Days campaign has raised the most money for the American Cancer Society Greater Pittsburgh Unit for eight consecutive years. The department also is an active participant in the national Susan G. Komen Race for the Cure to support breast cancer research and Pittsburgh’s Annual Walk for the Whisper that raises money for ovarian cancer research.

A volunteer recognition luncheon also is held annually to honor and celebrate the volunteers for their hard work and dedication to the program. The Volunteer and Community Services staff is continually looking for ways to meet the needs of patients and staff. In spring 2006, a book and magazine cart for patients, family, and visitors was added to the list of services as a result of donations from the volunteers at PNC Bank as well as the general public. The items from the cart are free for people to keep, as long as books and magazines continue to be donated.

“The UPMC Cancer Centers and UPCI Volunteer and Community Services Program has grown tremendously over the years, and will continue to play a vital role in the ongoing care of patients,” says Ms. Huntley.

Before Lisa Huntley became the director of the UPMC Cancer Centers and the University of Pittsburgh Cancer Institute’s (UPCI) Volunteer and Community Services Program, she was like most other volunteers, donating her time to patients fighting cancer to honor the memory of a loved one.

Ms. Huntley’s late husband, Grant Channell, was diagnosed with melanoma in 1989 at age 22. Two short years later, Mr. Channell’s cancer metastasized to his bones and lymph nodes, leading him to seek treatment from world-renowned melanoma specialist, John Kirkwood, MD, professor of medicine and dermatology, vice chairman for clinical research, Department of Medicine, UPMC; and director, Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute. The unusually virulent nature of Grant’s cancer ended his life in the fall of 1994.

About one year after her husband’s death, Ms. Huntley began volunteering at UPCI with a friend. Volunteering led to a greater interest in helping to develop the program. Ms. Huntley was hired as assistant director of the Volunteer and Community Services Program in fall 1997 and became director in fall 1999.

Ms. Huntley organizes the annual Grant Channell Memorial Golf Outing to support the Melanoma and Skin Cancer Program at UPCI. More than $120,000 has been raised from this event. This year’s activities were expanded to include the first annual Grant Channell Memorial Skin Cancer Screening, held in July 2006. More than 100 people participated in this prevention and early detection event, resulting in 22 referrals for a benign condition, and 12 referrals for biopsy.

The Lady With the Crazy Tights

Jennifer Kirsch is referred to as “the lady with the crazy tights” by the patients on 7-West at UPMC Shadyside Hospital where oncology patients are treated. When she is not volunteering for the UPMC Cancer Centers and UPCI Volunteer and Community Services Department, she is teaching seventh grade English at North Hills Junior High School.

Ms. Kirsch’s mother is a four-and-a-half-year breast cancer survivor whose oncologist is affiliated with Hillman Cancer Center. When Ms. Kirsch’s neighbor was diagnosed with advanced melanoma at age 12 in the fall of 2002, she decided she needed to become a volunteer. “Too many people get out the checkbook as their only form of donation,” says Ms. Kirsch. “Writing a check is too easy, and after seeing what my neighbor was going through, I decided I wanted to actively donate my time.”

Her neighbor had to undergo four weeks of Interferon treatments at Hillman Cancer Center, followed by 48 weeks at home, while being monitored closely by his cancer care team. He is now 16 years old, and patiently waiting to begin driving.

“The care my mother and my neighbor received at Hillman Cancer Center inspired me to volunteer there,” says Ms. Kirsch.

Ms. Kirsch volunteers for at least four hours one night a week during the school year. She has developed many wonderful relationships with patients since she began volunteering in October 2004 and has become known as the “lady with the crazy tights.” “I’ll make one person laugh or smile just by looking at my tights, I know I’ve brought him or her out of his or her element even for a moment,” she says.

Supporting an Ongoing Need

In addition to daily support, Volunteer and Community Services also hosts a number of special community events throughout the year to honor patients with cancer, while raising money and awareness. The Daffodil Days campaign has raised the most money for the American Cancer Society Greater Pittsburgh Unit for eight consecutive years. The department also is an active participant in the national Susan G. Komen Race for the Cure to support breast cancer research and Pittsburgh’s Annual Walk for the Whisper that raises money for ovarian cancer research.

A volunteer recognition luncheon also is held annually to honor and celebrate the volunteers for their hard work and dedication to the program. The Volunteer and Community Services staff is continually looking for ways to meet the needs of patients and staff. In spring 2006, a book and magazine cart for patients, family, and visitors was added to the list of services as a result of donations from the volunteers at PNC Bank as well as the general public. The items from the cart are free for people to keep, as long as books and magazines continue to be donated.

“The UPMC Cancer Centers and UPCI Volunteer and Community Services Program has grown tremendously over the years, and will continue to play a vital role in the ongoing care of patients,” says Ms. Huntley.

Before Lisa Huntley became the director of the UPMC Cancer Centers and the University of Pittsburgh Cancer Institute’s (UPCI) Volunteer and Community Services Program, she was like most other volunteers, donating her time to patients fighting cancer to honor the memory of a loved one.

Ms. Huntley’s late husband, Grant Channell, was diagnosed with melanoma in 1989 at age 22. Two short years later, Mr. Channell’s cancer metastasized to his bones and lymph nodes, leading him to seek treatment from world-renowned melanoma specialist, John Kirkwood, MD, professor of medicine and dermatology, vice chairman for clinical research, Department of Medicine, UPMC; and director, Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute. The unusually virulent nature of Grant’s cancer ended his life in the fall of 1994.

About one year after her husband’s death, Ms. Huntley began volunteering at UPCI with a friend. Volunteering led to a greater interest in helping to develop the program. Ms. Huntley was hired as assistant director of the Volunteer and Community Services Program in fall 1997 and became director in fall 1999.

Ms. Huntley organizes the annual Grant Channell Memorial Golf Outing to support the Melanoma and Skin Cancer Program at UPCI. More than $120,000 has been raised from this event. This year’s activities were expanded to include the first annual Grant Channell Memorial Skin Cancer Screening, held in July 2006. More than 100 people participated in this prevention and early detection event, resulting in 22 referrals for a benign condition, and 12 referrals for biopsy.
Thanks to the continued support of our donors, the University of Pittsburgh Cancer Institute and UPMC Cancer Centers are translating new discoveries in the laboratory into effective methods for preventing, detecting, and treating cancer. Gifts received during fiscal year 2006 are bringing renewed hope to cancer patients and their families in our region and beyond. It is with deepest gratitude that we recognize our partners — individuals, families, businesses, corporations, foundations, and organizations — for their ongoing support of our mission to build a future without cancer.

ENDOWED CHAIRS
An important number of endowed chairs support the mission of UPMC Cancer Centers and the University of Pittsburgh Cancer Institute. The names generated from individual gifts enable our scientists and physicians to engage in the strategic development of new initiatives, expand new initiatives, and forge new/frontiers in cancer treatment that benefit our patients and their families now and into the future.

The Clarks Worthington Benedum Endowed Chair in Radiation Oncology
The Michael C. Coyt Endowed Chair in Molecular Oncology
The Lawrence Ellis Endowed Chair in Hematology and Oncology
The Bernard Fisher Endowed Chair in Surgical Oncology
The Giant Eagle Foundation Endowed Chair in Cancer Genetics
The Hillman Endowed Chair in Oncology
The Arnold Palmer Endowed Chair in Cancer Prevention
The Simpson Family Endowed Chair in Thoracic Surgical Oncology
The Sands and Thomas Usher Endowed Chair in Melanoma
The UPMC Endowed Chair in Head and Neck Cancer Research

VISIONARY SOCIETY
Three dear beloved persons have given or helped to raise a cumulative total of $2 million or more in support of cancer research and care.

American Cancer Society, Incorporated
The Clarks Worthington Benedum Foundation
Highmark Foundation
Elsie H. and Henry L. Hillman Foundation
The Henry L. Hillman Foundation
The Hillman Foundation
Family and Friends of Albert P. Knox
Family and Friends of David C. Koch
Mario Lemieux Foundation
Richard King Mellon Foundation
Arnold D. Palumbo 2011 Charitable Trust
Mark E. Pasquerilla
PNF Financial Services Group and PNC Foundation
Mykel D. Simpson and Family
Sandra and Thomas Usher
Widder Brothers, Incorporated

FAMILY LEGACY SOCIETY
Often, a personal experience with cancer or the loss of a loved one to the disease opens a family to establish a fund that honors the patient through support of ongoing efforts in better diagnosis, prevention, and cancer research.

Suzanne Hill Miles-Endowment for Lung Cancer Research
Nathan S. Amstein Fund for Pancreatic Cancer Research
Berdichev Family Foundation
Endowed Scholars Program
The Harold Browning Ornitz Ovarian Cancer Research Scholars Fund
Ruth C. Brody Fund for Clinical Research on Pancreatic Cancer
Pam Burt Fund
Gregory T.H. Dutton Brain Tumor Research and Physician Education Endowed Fund
Peter E. Hedley Fund for Pancreatic Cancer Research
Dr. Herbert E. Jacob Memorial Fund
Barbara Kluny Memorial Scholarship Fund
Albert P. Knoxowe Research Fund
David C. Knox Memorial Fund
Mario Lemieux Primary Care and Cancer Research Fund
Scott Lamberts Endowed Chair in Cancer Research
Stanley M. Marks, MD, Endowed Research Fund
Drive Mathewson Entrepreneurship Fund
James A. Molika Jr. Research Endowed Fund
PNC Innovation Fund
Michael J. Parada Research Fund
Mark E. and Leah M. Pasquerilla
William’s Cancer Research Fund
Pasquerilla Cancer Geneomics and Proteomics Research Fund
The Spany Translational Research Core Facility
Joseph and Garvone Tenenbaum Memorial Fund
Wayne Fournier Pancreatic Cancer Research Fund
Dr. Leonard S. Zimbaldi Memorial Fund

ANNUAL GIVING
The Annual Fund provides vital support for the operations of clinical programs, basic and clinical research programs, recruitment of new physicians and scientists, seed money support, medical and patient education, and outreach programs. Those listed have made outstanding annual investments at the following designated levels.

CIRCLE OF HOPE
The Circle of Hope honors individual, family, foundations, and privately held companies that contribute a minimum of $1,000 to $4,999 in a calendar year. This list recognizes these vital contributors in 2005 and 2006, respectively.

American Municipal Securities
Buzzy Creamer
Lavon B. and Richard Clinton Bruce Americans
Luc R. Anderson
Anonymous (2)
Patty Baker and Jay Baker
Rookie Barrette and Tony Poli
Dorothy R. and Nicholas Oldfield III
The Brune Family
Nadeen E. Bognar
Mary Ann and Charles Bogumi
Lara and Andy Breit
Steve and Robert Browning
Jill Brody, Ph.D., and Alan Brody, MD, PhD
Tanner and Soil Brody
Barbara and Gerald C. Chan
Sandra S. and Richard A. Cohen
Carly and Cass Conelli
Barbara Ann and Robert A. Critzer
Randy and L. Van Dozier
Barbara and Randy Dixson
Janene Vincent Dixon
Dr. Dennis R. Dynko
Dr. Jeffrey D. Ellstein
Dr. Richard D. Feldman
Joe Zerbe
Dr. Richard A. Fronheiser
Andrew A. and Susan Gardner
Dr. Gary H. Green
Joyce H. and H. Robert Rowland
Catherine and Robert Rowland
Maxim and Dina Rowland
Richard Scully
Scott Seed
Dr. Jeffrey E. Seed
Maurice and Carol Seed
Sandra and Thomas Usher
Widder Brothers, Incorporated

Michael Felder
Diane Franz and Barry Lamond, MD
Brenna Frey, PhD, and Kenneth McCarthy, MD, PhD
Stephanie and Thomas Flannery
Kim H. and Daniel F. Fleischman
Foster Charitable Foundation
at the recommendation of Larry and Leo Foster
Jana K. France and Christine L. Allison
Chip Ganassie
Rebecca Garrett, MD, and Kenneth Feen, MD
The Gange Family
Sandra and Lee Goodman
Ellen R. Goodman
Gunn Family Foundation
Karyn B. and Vincent Gary
Thomas B. Grolsbl
Sara and Max Grom
Susan S. and Barry G. Guzman
Joseph Hardy Sr.
Eldogma Foundation
Heidi and Robert E. Hallock
Harriett L. and Ronald B. Harberman, MD
Steven Hafstott and Peter Karoluk Jr.
Douglas E. Harris, MD
Margaret M. and John R. Hill, MD
Elsie H. and Henry L. Hillman
Carolyn and Gerald Hiltz
Cathy and Sy Hober
Susan and Michael D. H. Howell
Joan and Samuel Jacobs, MD
Bonny and Robert Kamensonas
Ben and William Kemble
Karen L. and Joseph Kiley III, MD
Keith Kaidor, MD, and Jan Kizer
Mamie and Edward Kilkenny
Christopher H. Koch
Valerie M. Koch
Lauren andクラーク・Koch
A. Lottums and Spaulding"Lee
Natelev and Mark Lemmon
Robert Levit
Sally Levine
Richard T. Lewis
Shelley and Jeffrey Lipson
Christine and Daniel J. Lichten, MD
Carol and Thomas Lohan
Maggie Hard and Megan and Peter Miraglia
Stanley M. Marks, MD
Mary Family Charitable Foundation
Polly and William T. Marks
Myrna and Marks
Lizann and Stephen Marks
Mary and William T. Marsh
Jennifer and David M. McDevitt
Mark and Patricia Mccann
Barbara and Herbert Shear
Norton Family Foundation
Jacqueline and Jeffrey Shogan, MD
Patricia and William Snyder
Thomson Taylor, MD, and Marc Liang, MD
Rhea and Gaye Spaulding
Rory L. Stolberg
Seth Foundation
Marcia and Perry Steven
Passaro and Mark Tamborini
Tippin Foundation
Gayle L. Timms and Vincent Karydopulis
Sandra and Thomas Uhler
Bonnie W. and Thomas L. Verasky, Esq.
Kerrin and Kristen Wilm
Susan Hancock, MD
Dale and Harold Wheeler III
Jennifer and David Wheeler
Michael A. Wheelker II
JoAnn and Paul Wheeler
Jennifer and David Wheeler
Debi and Harold Wheeler III
Alicia and S. Donald Wiley
*deceased

Barbara A. Dappert, MD and Michael J. Becich, MD, PhD
Dana C. Denning
Kathy and David Deinick
Joan McClenahan
Brett R. and Richard A. Dietz
Sandra M. Dierks
Michael S. Dierks
Mary Ann and Charles Doorly
Jeffrey E. Edelson
Dr. David E. Edelson
Foundations
Patrick and Virginia Edlogging
Greg Egan
John J. Frennan Jr., Esq.
John and David Froud
Joyce and Stanley H. Goldstein
Nanne and Iris Gordon
Mary Jane and Carl G. Greenson
A. Richard Kaizen
Hann bm and Mario Kaizen
The Laci Family Foundation - Bids and Charles Loo
Simone and Scott Loranger
Helen Fruaçois Matthey
Gary Morell
Kirk Pomeranze
Sylta and Donald Lerman
Carol and John S. Salis
The Backman Family Foundation, Inc.
- Bonnne and Thomas Strum
- Mary Ann and Charles Sturman
- Troy and Lawrence M. Wagner
- Marianne and John J. Waldron
- Eleanor G. Wyckoff

PARTNERS FOR PROGRESS
($1,000 - $4,999)
Virginia and Don E. Ackerman
Barbara J. and Paul Adler, MD
Arnold and C. Eden
Martha and Anthony J. Allesio
Nicholas John Allegri
Matthew Ashley
Lawrence R. Andrews
Bonnie B. and Richard Paul Aaron, Esq.
Bill and Donna L. Antoni
Joan and Leon D. Antoni
Kimberly and Peter M. Augustino
Amadeo and Richard A. Atno
Korean and Susan Baten
William B. Baren
Ann and William B. Barn Jr.
Susan and David Barn
Barbara A. Deppe, MD and Michael J. Biecz, MD, PhD
Elaine Bollin
Patt and Samsuel S. Bressman
Maryann Bressman
William B. Britton
Karen and Susan Bress
Jennifer and David B. Bronk
Jon and Arthur Dean Boyd, MD
- Bonnie and Thomas Strauss
- Mary Ann and Charles Sturman
- Troy and Lawrence M. Wagner
- Marianne and John J. Waldron
- Eleanor G. Wyckoff

LEADERSHIP CIRCLE
($5,000 - $9,999)
Susan and Michael Blyuke
Susan and Robert Chase
Elizabeth and Michael Concase
James and William C. Converse
Robert and Robert Corey
Ranny and Jay Forpman
John J. Frennan Jr., Esq.
Joyce and Donald Froud
Joyce and Stanley H. Goldstein
Nanne and Iris Gordon
Mary Jane and Carl G. Greenson
A. Richard Kaizen
Hann bm and Mario Kaizen
The Laci Family Foundation - Bids and Charles Loo
Simone and Scott Loranger
Helen FruaFrançois Matthey
Gary Morell
Kirk Pomeranze
Sylta and Donald Lerman
Carol and John S. Salis
The Backman Family Foundation, Inc.
- Bonnne and Thomas Strum
- Troy and Lawrence M. Wagner
- Marianne and John J. Waldron
- Eleanor G. Wyckoff
ESTATES AND TRUSTS
LPSC Cancer Centers and the University of Pittsburgh Cancer Institute gratefully acknowledge gifts from the following individual estates and trusts:

- Estate of Richard J. Rotunio
- Estate of Harri L. Browning
- Estate of Jane M. Epitrop
- Estate of C. Gibson and Valma R. Shover

BUSINESS, CORPORATIONS, ADVOCACY, ASSOCIATIONS, AND OTHER GROUPS
LPSC Cancer Centers and the University of Pittsburgh Cancer Institute gratefully acknowledge gifts of $250 or more from business, corporation, advocacy associations, and other groups.

- ($100,000 +) - 99 Lumber Company
- American Cancer Society, Incorporated
- American Society of Hematology
- American Society for Blood Cell Research
- Anesthesiologists
- Fraternity and Sorority Life Office
- University of Pittsburgh Magee-Womens Research Institute
- University of Pittsburgh Medical Center
- University of Pittsburgh Music Festival

- ($50,000 - $99,999)
- Aquisitions Sales and Marketing Company
- American Eurocopter Company
- American Institute of Dental Hygienists
- American Heart Association
- Anonymous
- University of Pittsburgh Magee-Womens Research Institute
- University of Pittsburgh University Hospitals of Western Pennsylvania

- ($25,000 - $49,999)
- Atrius Media Services, Inc.
- BAX, Pittsburgh, Inc.
- Bear Hill
- Beth Israel Hospital
- CDS, Inc.
- Colgate-Palmolive
- The Connoisseur

- ($10,000 - $24,999)
- Advent Life Sciences
- Advantage Life Sciences
- Allstate Life Sciences

- ($1,000 - $4,999)
- Amgen Therapeutics, Inc.
- Anon

- ($1,000 - $4,999)
- Amgen Therapeutics, Inc.
- Anon

- ($250 - $999)
- Airports Council International - North America
- AllIn Good TastProductions, Inc.
- Allstate Life Sciences

- ($100 - $249)
- Allen & Heath
- Ankrom-McDermott

- ($25 - $99)
- Airports Council International - North America
- AllIn Good TastProductions, Inc.
- Allstate Life Sciences

- ($10 - $24)
- Allstate Life Sciences
- Allstate Life Sciences

- ($1 - $9)
- Allstate Life Sciences
- Allstate Life Sciences
The Hillman Cancer Center's annual gala, held May 3 at the UPMC Sports Performance Complex on Pittsburgh’s South Side, generated $8.2 million in sponsorships and contributions for patient care and cancer research. This included $2 million from The Arnold D. Palmer Charitable Trust for a new initiative in cancer prevention; $1 million from Sandra and Tom Usher to support melanoma research; $1 million from an unrestricted grant from the PNC Financial Services Group. The event was hosted by honorary celebrity chair Arnold Palmer, honorary chairs Ellis and Henry Hillman, and event co-chairs Sharon and Jim Rohr and Sandra and Tom Usher.

The highlight of the evening was a surprise performance by Broadway icon Liza Minnelli.
2006 ASCO Highlights

Researchers from the University of Pittsburgh School of Medicine presented findings from more than 30 studies at the American Society of Clinical Oncology’s annual meeting in Atlanta. Presentation highlights included an evaluation of the impact of race and income on women’s experiences with metastatic breast cancer. The study led by Margaret Quinn Rosenzweig, PhD, looked at how women perceived barriers to treatment and symptom management by evaluating the experiences of 51 women who were subdivided according to varied groupings of race and income. Researchers found that low-income African American women were more likely to report physical and social distress and uncertainty about their future than other groups evaluated in the study. Results revealed the crucial influence health care providers can have on improving outcomes for patients by tailoring care more appropriately to provide women with the tools they need to better cope with advanced breast cancer.

In a study of a new chemotherapy drug for liver cancer, researchers found that the development of a skin rash correlated directly with the patient’s response to treatment. The study included 57 patients with advanced liver, gallbladder, and bile duct cancers who were not candidates for surgery and who were treated with lapatinib. Upon evaluating the toxic effects in patients, researchers found that 30 patients developed a skin rash from lapatinib. Patients who developed the rash lived for an average of 10 months compared to five months for those who did not develop a rash. According to Ramesh K. Ramalingam, MD, the study has implications for predicting growth of cancer and could be a method to identify patients with advanced cancer who would most likely respond to this treatment.

Suresh Ramalingam, MD, received a Clinical Research Development Award for a study on vorinostat, one of a class of drugs called histone deacetylases, thought to stop the growth of tumor cells by altering the expression of genes necessary for cancer cell growth. In the study, Dr. Ramalingam examined the effects of three different doses of vorinostat on patients with head and neck cancer, bladder cancer, and mesothelioma to see how safely it could be added to standard chemotherapy. Eleven out of 28 patients had a partial response to treatment, and the disease was stabilized in an additional seven patients.

Potential New Treatment for Breast Cancer

Victor G. Vogel, MD, MHS, director, Magee-Women Breast Cancer Program at UPMC Cancer Centers, and colleagues from the National Surgical Adjuvant Breast and Bowel Project found that the osteoporosis drug raloxifene was equally effective in reducing the risk of breast cancer as the breast cancer treatment drug tamoxifen, according to a study published in the June 21 issue of the Journal of the American Medical Association.

Compared to tamoxifen, raloxifene also was safer in terms of causing lower uterine cancers and blood clots. Raloxifene and tamoxifen are both effective in reducing the risk of invasive breast cancer but each has potential breast and breast side effects that women and their physicians need to consider, according to Dr. Vogel.

UPMC and Lilly Oncology Partner for Awareness

UPMC and Lilly Oncology recently collaborated to bring two unique cancer awareness programs to the Pittsburgh area. Oncology on Canvas: Expressions of a Woman’s Cancer Journey is a worldwide traveling art exhibit that focuses on the millions of people affected by women’s cancers and raises awareness of the benefits of art therapy as a means of coping with cancer. Cancer patients, family, friends, and health care providers from 23 countries created the more than 400 pieces of artwork that make up the exhibit. Selections from the exhibit were displayed at Hillman Cancer Center; UPMC Cancer Center, Upper St. Clair; UPB Cancer Center, Steubenville; and UPMC Jameson Cancer Center throughout August and September. Lilly also partnered with UPMC to present a special A Reason to Hope lecture featuring DeeDee Jonrowe, breast cancer survivor and Iditarod competitor. Ms. Jonrowe shared her journey as a breast cancer survivor, her lifestyle as a kennel owner and trainer, her 24 years of racing in the Alaskan Iditarod, and the encouraging promise of improved cancer treatments at community lectures in Pittsburgh and Greensburg.

Remembering Mayor O’Connor

UPMC Cancer Centers and the University of Pittsburgh Cancer Institute join the City of Pittsburgh and the western Pennsylvania region in mourning the death of Mayor Bob O’Connor of complications from primary central nervous system lymphoma. A memorial fund has been established in Mr. O’Connor’s honor to support lymphoma research. Contributions can be sent to UPCI Development Department, UPMC Cancer Paulinon, Suite 18, 5150 Centre Ave., Pittsburgh, 15232. Checks should be made payable to UPCI and include Mr. O’Connor’s name in the memo line. For more information, call 412-623-4900.

Preclinical Gene Therapy Advances in Ovarian Cancer

David L. Bartlett, MD, chief, Division of Surgical Oncology, and a team of researchers reported promising results that may lead to advances in the treatment of ovarian cancer at the American Society of Gene Therapy annual meeting.

The team inoculated mice with an ovarian cancer cell line, treating some immediately with a genetically engineered vaccine containing a gene that induces cell death, or apoptosis. Treatment was delayed 30 to 60 days in another group of mice and withheld entirely in control mice. Immediate treatment completely prevented tumor growth in 90 percent of the mice, and delayed treatment significantly inhibited tumor growth. These promising preclinical results may soon be translated into a clinical trial for women with recurrent ovarian cancer.
UPMC Cancer Centers offers cancer patients exceptional care and innovative treatments close to home. Working in tandem with the University of Pittsburgh Cancer Institute, western Pennsylvania’s only National Cancer Institute-designated Comprehensive Cancer Center, UPMC Cancer Centers provides the latest advances in cancer prevention, detection, diagnosis, and treatment at community-based locations throughout the region.

The University of Pittsburgh Cancer Institute comprises the academic and research activities for cancer at the University of Pittsburgh and the University of Pittsburgh Medical Center.

For information about supporting cancer research efforts and patient care at the University of Pittsburgh Cancer Institute and UPMC Cancer Centers, contact us at 412-612-4700.